Abstract
İn this poper we described an 8-month-old girl with vincristine induced cranial polyneuropathy who was succesfully treated with pyridoxine and pyridostigmine. The patient was diagnosed as preB cell ALL and received chemotherapy according to the previously described St. Jude total therapy XIII studies. Twenty days after the fourth dose of vincristine (cumulative dose 2.8 mg), she developed ptosis. Neurological examination revealed ptosis with normal pupillary and corneal reflexes. Pyridoxine and pyridostigmine was initiated as an attempt for neuroprotection and neuroregeneration. Ptosis markedly improved after 6 days and completely resolved after two weeks. Both agents were given for 3 weeks and were well tolerated without any side effects. During the follow up period we did not observe residue recurrence of ptosis
Keywords: -
References
- Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neu- ropathy. J Neurol 2002; 249: 9-17.
- Legha SS. Vincristine neurotoxicity. Pathophysiology and mana- gement. Med Toxicol 1986; 1 : 421-427.
- Bay A, Yilmaz C, Yilmaz N, Oner AF. Vincristine induced cranial polyneuropathy. Indian J Pediatr 2006; 73 : 531-533.
- Ann Pharmacother 2000; 34 : 1136-1138.
- Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998; 18 : 1304-1307.
- . Pediatr Blood Cancer 2004; 42 : 287-288.
- Jackson DV, Jr., Pope EK, McMahan et RA Cooper MR, Atkinsın, Callahan RD, Paschold EM, Grimm RA, Hopunins 10, Muss HB. Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neurooncol 1986; 4 : 37-41.
